SOURCE: IntelliCell BioSciences, Inc.

IntelliCell BioSciences, Inc.

March 12, 2014 13:57 ET

IntelliCell BioSciences Raises Capital for Strategic Growth

NEW YORK, NY--(Marketwired - Mar 12, 2014) -  IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today that it has closed on a round of financing from Yorkville Advisors, LLC.

IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a turning point for IntelliCell BioSciences. With the infusion of this capital, we will not only be able to fully open our New York flagship center, but also open an additional strategically placed remote cellular lab. We believe this will allow us to implement our business model." 

According to Mark Angelo, "We are pleased to have closed this transaction with IntelliCell and look forward to working with management over the course of our investment."

Owen May stated, "We are extremely excited about IntelliCell BioSciences's stem cell technology and we believe that the new relationship with the Andrews Research and Education Foundation will be a pivotal step in better assessing the use of this therapy in sports medicine."

About IntelliCell Biosciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

About Yorkville Advisors

Yorkville Advisors is a global alternative investment manager. Over the last decade, Yorkville has been specializing in providing flexible, innovative debt and equity investments, and financing to publicly listed companies in a variety of sectors.

Yorkville tailors its transactions on an investment by investment basis, which may include debt and equity investments, bridge financings, asset-backed or SEDA-backed notes, equity swap facilities and, straight equity participation.

Yorkville has offices in London and New Jersey.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information

  • Contact:

    IntelliCell BioSciences, Inc.
    Investor Relations
    Anna Rhodes
    Email Contact
    (646) 576-8308